Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Vir Biotechnology, Inc.NASDAQ: VIR

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns positive

Q1 FY2026 other non-cash items was $13.18M, compared with -$136K a year earlier. Trailing-twelve-month other non-cash items was $14.61M.

Context

  • Other non-cash items amounted to 2.3% of revenue in FY2025, down 91.4 pp from a year earlier.
  • Other non-cash items increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near $13.18M or moves back toward the trailing-twelve-month quarterly average of $3.65M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.18M+336.7% QoQ
Last fiscal yearDec 2025
-$1.57M-102.3% YoY
LTMMar 2026
$14.61M-85.2% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9791.9%——
1 year-102.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
(1.57M) USD
Year-over-year change
-102.3%

Other Non-Cash Items vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -85.2% is the 8th highest of 10, against a peer median of +65.5%.
  • Other non-cash items amounts to 22.3% of revenue for VIR, versus a peer median of 14.7%.
VIR Competitors
Other Non-Cash Items for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$571.94M USD+1039.2%-28.1%60.8%
BNTXBioNTech SELTM Jun 2026€491.35M EUR+224.1%—18.6%
MRNAModerna, Inc.LTM Sep 2026$213M USD+373.3%—8.4%
NVAXNovavax, Inc.LTM Mar 2026$113.61M USD+433.2%-32.1%19.1%
VALNValneva SELTM Mar 2026€46.24M EUR+65.5%-3.1%29.6%
ABUSArbutus Biopharma CorporationLTM Mar 2026$20.58M USD-4830.2%-3.0%10.7%
VIRVir Biotechnology, Inc.LTM Mar 2026$14.61M USD-85.2%—22.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$3.79M USD-62.4%-3.3%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$1.79M USD+10.4%—2.5%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.33M USD-719.1%—1.9%
Peer median (excluding VIR) —+65.5%-3.3%14.7%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Depreciation & Amortization5.81M6.78M19.45M14.56M21.15M
Deferred Income Tax15.19M(15.19M)(1.06M)(2.95M)0
Stock-Based Compensation83.78M102.08M078.46M49.07M
Change in Working Capital(628.39M)665.37M(304.59M)(84.01M)(22.45M)
Accounts Receivables(773.08M)770.04M(565K)(6.51M)0
Inventory52.82M0000
Accounts Payables(171K)797K732K(988K)5M
Other Working Capital92.04M(105.47M)(304.76M)(76.51M)(27.44M)
Other Non-Cash Items(52.56M)388.37M122.48M69.55M(1.57M)
Operating Cash Flow(47.59M)1.66B(778.79M)(446.35M)(391.78M)
Capital Expenditures(21.82M)(68.01M)(21.57M)(7.3M)(4.83M)
Acquisitions (Net)140.81M0100K3.37M253K
Purchases of Investments(420.24M)(1.48B)(2.02B)(1.24B)(886.33M)
Sales of Investments301.24M351.51M2.2B1.74B1.2B
Other Investing Activities(140.81M)0000
Investing Cash Flow(140.81M)(1.19B)164.73M499.37M310.37M
Debt Repayment(259K)(260K)(287K)(165K)(361K)
Common Stock Issued85.21M28.46M7.77M4.55M4.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.38M6.56M(100K)00
Financing Cash Flow100.33M34.76M7.38M4.39M3.79M
Effect of Forex Changes00208K00
Net Change in Cash(88.07M)504.55M(606.47M)57.4M(77.63M)
Free Cash Flow(69.41M)1.6B(800.36M)(453.65M)(396.61M)

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.